Type 1 Diabetes Biomarkers

a biomarker and type 1 diabetes technology, applied in the field of biomarkers, can solve the problems of serious co-morbidities, personal and societal burdens in financial and quality of life, and achieve the effects of improving the sensitivity of detection in t1d patients, and improving the risk prediction model

Inactive Publication Date: 2016-07-07
ARIZONA STATE UNIVERSITY +1
View PDF2 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0005]Identifying markers that present prior to the development of our currently used autoantibodies (AAbs) could improve the risk prediction models. Thus, the embodiments disclosed herein relate to the identification of AAb biomarkers in T1D so as to increase the sensitivity of detection in T1D patients and improve the T1D risk prediction model.

Problems solved by technology

T1D patients are dependent on lifelong exogenous insulin but this is not a cure and in the long term there are serious co-morbidities.
This leads to both personal and societal burdens in terms of financial and quality of life indicators.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Type 1 Diabetes Biomarkers

Examples

Experimental program
Comparison scheme
Effect test

example

[0016]Sera from T1D patients contain AAbs to human self-proteins. Thus, the sero-reactivity to 10,000 human proteins with sera from T1D patients and measured bound IgG. We scaled down the candidate number for validation in an independent sample set. In the knowledge based approach, we performed ELISA on 126 pancreas enriched genes and validate the candidates in an independent sample set. Taken together, 17 potential autoantigens were identified with sensitivities ranging from 10-27% at 95% specificity (Table 1).

[0017]Rapid antigenic protein in situ display (Rapid) ELISA was performed to confirm the sensitivities of autoantibodies biomakers. 96-well ELISA plates (Corning, Me.) were coated with 10 ng / mL anti-glutathione S-transferase (GST) antibody (GE Healthcare, Pa.) in coating buffer (0.5 M carbonate bicarbonate buffer, pH 9.6) overnight at 4° C. On the next day, coated plates were washed 3 times with PBST and blocked with 5% milk-PBST (0.2% Tween) for 1.5 hrs at room temperature (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
pHaaaaaaaaaa
lengthaaaaaaaaaa
Login to view more

Abstract

Type 1 diabetes (T1D) patients make antibodies to self-proteins that are potential biomarkers for early detection and risk prediction. We have identified seventeen antigens as biomarkers for early diagnosis and risk prediction of T1D, including the antigens MLH1, MTIF3, PPIL2, NUP50, TOX4, FIGN, C9orf142, ZNF280D, HES1, QRFPR, CTRC, SNX6, SYTL4, ELA2A, IGRP, PAX6, and HMGN3.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application No. 62 / 100,775, filed Jan. 7, 2015, the entire contents of which are incorporated herein in their entirety by reference.FIELD OF THE INVENTION[0002]This disclosure relates to biomarkers for the prediction of Type 1 diabetes (T1D) onset and for diagnosing T1D.BACKGROUND OF THE INVENTION[0003]T1D is one of the most common juvenile autoimmune diseases. It is characterized by progressive autoimmune destruction of pancreatic beta cells. The incidence of T1D is increasing worldwide. T1D patients are dependent on lifelong exogenous insulin but this is not a cure and in the long term there are serious co-morbidities. This leads to both personal and societal burdens in terms of financial and quality of life indicators. At the time of T1D diagnosis, it is thought that potentially 70%-90% of pancreatic beta cells have been destroyed. Therefore early diagnostic and prognostic mar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2800/50G01N2800/042G01N33/564
Inventor LABAER, JOSHUAQIU, JIBIAN, XIAOFANGSCHATZ, DESMOND A.WASSERFALL, CLIVE H.ATKINSON, MARK A.
Owner ARIZONA STATE UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap